Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 08/08/25
Will Gilead's Beat-And-Raise Help It Leapfrog Its 50-Day Line Ceiling?Investors Business Daily • 08/07/25
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?Zacks Investment Research • 08/04/25
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challengesWSJ • 08/01/25
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/31/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILDPRNewsWire • 07/27/25
Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future SalesBenzinga • 07/25/25
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV PreventionBusiness Wire • 07/25/25
Gilead Sciences to Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025Business Wire • 07/24/25
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to KnowZacks Investment Research • 07/22/25
Human Immunodeficiency Virus (HIV) 7MM Drug Forecast and Analysis Report 2023-2033 | Market to Reach $32.1 Billion - Gilead Sciences to Remain the Leading PlayerGlobeNewsWire • 07/17/25